Clinical study on the treatment of abnormal uterine hemorrhage due to anovulatory disorder with deoxygestrel ethinylestradiol tablets and ethinylestradiol cyproterone tablets

Journals

Online: 17 October 2022; Volume 1, Issue 1, No.3 PDF DOWNLOAD

Title：
Clinical study on the treatment of abnormal uterine hemorrhage due to anovulatory disorder with deoxygestrel ethinylestradiol tablets and ethinylestradiol cyproterone tablets
Author：
Yanti Wen¹, Guiying Liu²
Author Affiliation：
1. Shenzhen Polytechnic, Shenzhen, China
2. Zhaoqing Hospital of Traditional Chinese Medicine, Zhaoqing, China

Abstract

Objective: to compare and analyze the clinical value of oxygestrel ethinylestradiol tablets and ethinylestradiol cycloproprogesterone tablets in the treatment of abnormal uterine bleeding in patients with ovulation disorders and their

inhibitory effects on sex hormones. Methods: 76 patients with abnormal uterine bleeding due to ovulation disorder admitted from January 2018 to January 2021 were selected as the study subjects, and all patients were randomly divided into the Observation Group and the Control Group, with 38 patients in each group. The patients in the Control Group were treated with Deoxygestrel ethinyl estradiol tablets, and the patients in the Observation Group were treated with ethinyl estradiol cycloproprogesterone tablets. The changes of clinical indicators hormone levels, adverse reactions during treatment, and quality of life after treatment were compared between both groups. Results: There was no significant difference in hemoglobin (Hb) level, endometrial thickness, menstrual time and menstrual volume between both groups before treatment (P>0.05). After treatment, the Hb level in both groups increased, while that in the Observation Group was higher than that in the Control Group (P<0.05). The endometrial thickness, menstrual time and menstrual volume decreased, while that in the Observation Group was lower than that in the Control Group (P<0.05); there was no significant difference between both groups in luteinizing hormone (LH), follicle stimulating hormone (FSH) and estradiol (E2) before treatment (P>0.05). After treatment, the levels of LH, FSH and E2 in both groups were lower than those in the Control Group (P<0.05); there was no significant difference in the total incidence of adverse reactions between both groups (P>0.05); after treatment, the scores of quality of life in both groups were higher, and the scores in the Observation Group were higher than those in the Control Group (P<0.05). Conclusion: the clinical effect of ethinyl estradiol cycloproprogesterone tablets on patients with abnormal uterine bleeding due to ovulation disorder is better than that of oxygestrel ethinyl estradiol tablets, which can reduce the clinical symptoms of patients, inhibit the sex hormones, have

lower adverse reactions, and can improve the quality of life of patients.

References

[1] WANG Yu-zhu, SUN Yu, BAI Wen-pei. Research progress of abnormal uterine bleeding related to ovulation disorder [J]. Chinese Contemporary Medicine, 2019, 26 (13): 27-29, 33

[2] TIAN Qin-jie, HUANG He. Definition, naming, classification and diagnosis of abnormal uterine bleeding [J]. Journal of Practical Obstetrics and Gynecology, 2016, 32 (12): 881-883

[3] Motta T, Lagand AS, Valenti G, et al. Differential diag-nosis and management of abnormal uterine bleeding in adolescence[J]. Minerva Ginecol, 2017, 69(6): 618-630.

[4] Gynecological Endocrinology Group, Branch of Obstetrics and Gynecology, Chinese Medical Association. Guidelines for the diagnosis and treatment of abnormal uterine bleeding due to ovulation disorder [J]. Chinese Journal of Obstetrics and Gynecology, 2018, 53 (12): 801-807

[5] YU Xin-yu. The effect of levonorgestrel intrauterine contraceptive system combined with mifepristone on the improvement of menstrual volume and quality of life of patients after diagnostic curettage for perimenopausal functional uterine bleeding [J]. Modern Medical Imaging, 2018, 27 (5): 1717-1718

[6] XIE Yun, REN Bao-hui, LI Hong-xia, et al. Clinical observation and analysis of 60 cases of abnormal uterine bleeding with ovulation disorder in reproductive age [J]. Chinese Journal of Eugenics and Genetics, 2018, 26 (6): 72-73

[7] ZHENG Hui-xian. Observation on the efficacy of Peikun pill combined with levonorgestrel in the treatment of perimenopausal dysfunctional uterine bleeding [J]. Modern Medicine and Clinical Medicine, 2019, 34 (6): 1797-1800

[8] JIANG Feng-ying. The efficacy of Diane-35 in the treatment of perimenopausal abnormal uterine bleeding and its influence on the level and metabolism of sex hormones [J]. Heilongjiang Medical Journal, 2020, 44 (8): 1081-1084

[9] MAO Wei. Treatment of polycystic ovary syndrome by Mafulong, Daying-35 and Yousiming [J]. Jilin Medical Journal, 2014, 35 (27): 6015-6016